Solutions Designed for In-Stent Restenosis
An estimated 200,000 stents are placed in the femoral and popliteal arteries of PAD patients in the U.S. every year. Of these, 30-40% are estimated to develop in-stent restenosis within 2 years of implantation.1
BD is dedicated to providing you with innovative solutions for treating your patients that develop in-stent restenosis.
Vessel preparation using only pre-dilatation with PTA catheter was studied with the Lutonix™
DCB in the LEVANT 2 clinical study.
angioplasty, after appropriate vessel preparation, of de novo, restenotic, or in-stent restenotic lesions up to 300 mm in length in native superfi cial femoral or popliteal arteries with reference vessel diameters of 4-7 mm.
The Lutonix™ 035 Drug Coated Balloon PTA catheter is indicated for percutaneous transluminal
remove thrombus from native peripheral arteries or peripheral arteries fi tted with stents, stent grafts or native or artifi cial bypasses. The Rotarex™
suitable for atherectomy/thrombectomy; in the cardiopulmonary, coronary, carotid, cerebral and renal vasculature; in vessels that are undersized for the device used; and in the venous vasculature.
Atherectomy System is intended for use as an atherectomy device and to break up and Atherectomy System is contraindicated in patients not
as vessel preparation for the Lutonix™ The Rotarex™
The Rotarex™
Atherectomy Device has not been clinically studied Drug Coated Balloon.
bd.com BD, Tempe, AZ, USA, 1 800 321 4254
Please consult product labels and instructions for use for indications, contraindications, hazards, warnings, and precautions. BD, the BD logo, Lutonix, and Rotarex are trademarks of Becton, Dickinson and Company or its affi liates. © 2022 BD. All Rights Reserved. © 2022 Illustrations by Mike Austin. BD-48190
1 Walker C. Interventional treatment of superfi cial femoral artery in-stent restenosis. Vascular Disease Management 07/01/2015;
www.vasculardiseasemanagement.com.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40
